Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 896-900

  Buchegger, Franz ^a,b   Antonescu, Cristian ^c   Helg, Claudine ^d   Kosinski, Marek ^a   Prior, John O ^a   Delaloye, Angelika Bischof ^a   Press, Oliver W ^e,f   Ketterer, Nicolas ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

^d Clinic of Genolier   (Switzerland)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

131I tositumomab; Long term efficacy; Radioimmunotherapy

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; CLEMASTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PARACETAMOL; POTASSIUM IODIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; EDEMA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPHADENITIS; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PAIN; PNEUMONIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SWITZERLAND; THYROIDITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW DISEASES; DRUG RESISTANCE, NEOPLASM; ENGLAND; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE I, RECOMBINANT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; REMISSION INDUCTION; SWITZERLAND; UNITED STATES;

EID: 79958102423     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.087460     Document Type: Article

References (20)

1. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290. (Pubitemid 26105537)
2. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
3. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270. (Pubitemid 46606402)
4. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449. (Pubitemid 40175970)
5. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1469-1479. (Pubitemid 41103630)
6. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712-719. (Pubitemid 46224170)
7. 131I-rituximab in routine clinical practice: 10-year, single institution experience of 142 consecutive patients. Blood. 2011;117:45-52.
8. 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. J Exp Clin Cancer Res. 2011;30:16.
9. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573. (Pubitemid 46291820)
10. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst. 1991;83:627-632.
11. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997;57:447-453. (Pubitemid 27081662)
12. Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1-4.
13. 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer. 2006;94:1770-1776.
14. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8, suppl):14S-20S.
15. Kaminski MS, Zelenetz AD, Press OW. Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low grade and transformed B-cell lymphomas. Paper presented at: 52nd ASH annual meeting and exposition; December 4-7, 2010; Orlando, FL.
16. Martin P, Coleman M, Furman RR, et al. Fludarabine plus I-131 tositumomab as initial treatment for follicular lymphoma: half of patients in remission at over 10 years median followup. Paper presented at: 52nd ASH annual meeting and exposition; December 4-7, 2010; Orlando, FL.
17. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156-5164.
18. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576-4582. (Pubitemid 40807274)
19. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906. (Pubitemid 46613489)
20. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)